Zhai Qihui Jim, Rosen Daniel Gustavo, Lu Karen, Liu Jinsong
Department of Pathology, The Methodist Hospital, Houston, Texas, USA.
Int J Clin Exp Pathol. 2008 Jan 31;1(6):502-9.
Microsatellite instability (MSI) due to defects in DNA mismatch repair genes may be involved in the development of a subset of human ovarian carcinomas. The role of one such gene, hMSH6, in ovarian cancer is not well documented. We investigated the expression of hMSH6 protein in different histotypes of ovarian carcinoma and the associations between loss of hMSH6 protein and tumor grade, disease stage, familial history of cancer and patient survival. We stained an ovarian carcinoma tissue microarray consisting of formalin-fixed, paraffin-embedded tissue samples from 322 patients with an anti-hMSH6 antibody and scored the results semiquantitatively as negative or positive. Twelve cases were excluded owing to loss of cores during staining. Absence of hMSH6 protein was noted in 20 of 230 serous carcinomas (8.7%), in 7 of 16 clear cell carcinomas (43.7%), in 4 of 34 endometrioid carcinomas (11.7%), in 1 of 14 malignant mixed Müllerian tumors, 2 of 6 mucinous carcinomas, 0 of 2 transitional cell carcinomas and in 0 of 8 undifferentiated carcinomas. Loss of hMSH6 protein was not associated with survival, patient age, tumor grade, or disease stage but was associated with clear cell, mucinous and endometrioid carcinoma histology (P<0.007). These findings indicate that loss of hMSH6 expression in ovarian carcinoma is more common in certain histologic subtypes, particularly in clear cell, endometrioid, and mucinous carcinoma, suggesting that loss of hMSH6 function may participate in the pathogenesis of these subtypes of cancer. Loss of hMSH6 expression did not predict survival and was not associated with disease stage, tumor grade, patient age or family history of cancer.
由于DNA错配修复基因缺陷导致的微卫星不稳定性(MSI)可能与一部分人类卵巢癌的发生发展有关。其中一个这样的基因hMSH6在卵巢癌中的作用尚无充分文献记载。我们研究了hMSH6蛋白在不同组织学类型卵巢癌中的表达情况,以及hMSH6蛋白缺失与肿瘤分级、疾病分期、癌症家族史和患者生存率之间的关联。我们用抗hMSH6抗体对一个由322例患者的福尔马林固定、石蜡包埋组织样本组成的卵巢癌组织芯片进行染色,并将结果半定量地评为阴性或阳性。由于染色过程中芯块丢失,排除了12例。在230例浆液性癌中有20例(8.7%)未检测到hMSH6蛋白,16例透明细胞癌中有7例(43.7%),34例子宫内膜样癌中有4例(11.7%),14例恶性混合性苗勒管肿瘤中有1例,6例黏液性癌中有2例,2例移行细胞癌中均未检测到,8例未分化癌中也均未检测到。hMSH6蛋白缺失与生存率、患者年龄、肿瘤分级或疾病分期无关,但与透明细胞、黏液性和子宫内膜样癌组织学类型有关(P<0.007)。这些发现表明,hMSH6在卵巢癌中的表达缺失在某些组织学亚型中更常见,尤其是在透明细胞、子宫内膜样和黏液性癌中,提示hMSH6功能缺失可能参与了这些癌症亚型的发病机制。hMSH6表达缺失不能预测生存率,也与疾病分期、肿瘤分级、患者年龄或癌症家族史无关。